HCQ restriction in the U.S.: What a disaster
Andy Schlafly shares positive stats from nations that had greater access to hydroxychloroquine
By Andy SchlaflyPublished June 30, 2020 at 7:16pm
As the media sound alarm bells about a possible second wave of COVID, we should firmly reject another nationwide economic shutdown enforced by stay-home orders and mandatory masks. Republicans need an approach that gets Americans back to attending church, Trump rallies and in-person voting at local polling places.
Forcing everyone to wear a mask, even while jogging or boating, will do nothing to conquer the virus or restore public confidence. Sending the expensive new intravenous drug Remdesivir to hospitals, for COVID patients on their deathbed, will do nothing to calm public fears.
President Trump should turn instead to the approach liberals fear and oppose the most: making hydroxychloroquine (HCQ) widely available to the American people. Trump may not realize that the medication he took in May to successfully protect himself against COVID-19 is still inaccessible to most Americans.
A recent compilation of 50 studies of HCQ shows that it is effective as a prophylaxis and as early treatment, but less effective when used late in the course of the disease. This is similar to other anti-virals, such as Tamiflu, which are best given within 24 or 48 hours of first exposure to influenza.
Prophylaxis (or prophylactic) means using a medication to keep from getting sick or to minimize symptoms if you do get sick. Yet Americans are prevented from obtaining HCQ within a few days of exposure to the virus, before they develop symptoms or soon after.
No comments:
Post a Comment